降脂药物在NAFLD患者中的合理应用

doi:10.3969/j.issn.1672-5069.2016.02.005

Abstract

Zhong Bihui. Appropriate application of lipid-regulating agents in patients with non-alcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 143-146.

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南（2010年修订版）. 中华肝脏病杂志,2010,18（31）:163-166.
[2] Donnelly KL,Smith CI,Schwarzenberg SJ,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Investig,2005,115（5）:1343-1351.
[3] Liao XH,Cao X,Liu J,et al. Prevalence and features of fatty liver detected by physical examination in Guangzhou. World J Gastroenterol,2013,19（32）:5334-5339.
[4] 叶俊钊,李敏睿,吴艳琴,等. 中国人群非酒精性脂肪性肝病单中心死亡原因分析.中华医学会第十五次全国消化系病学术会议,2015,PO-137.
[5] 胡大一,郭艺芳. 2014年中国胆固醇教育计划血脂异常防治专家建议. 中国循环杂志,2014,35（6）:410-411.
[6] Reiner Z,Catapano AL,De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. Rev Esp Cardiol, 2011,64（12）:1161-1168.
[7] Stone NJ,Robinson J,Lichtenstein AH,et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2013,63（25）:2889-2934.
[8] Chatrath H,Vuppalanchi R,Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Sem Liver Dis,2012,32（1）:22-29.
[9] Foster T,Budoff MJ,Saab S,et al. Atorvastatin and antioxidants for the treatment of nonalcoholicfatty liver disease:the St Francis Heart Study randomized clinical trial. Am J Gastroenterol,2011,106（1）:71-77.
[10] Targher G,Day CP,Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New Engl J Med, 2010,363（14）:1341-1350.
[11] 血脂相关性心血管剩留风险控制中国专家共识组.血脂相关性心血管剩留风险控制中国专家共识.中国心血管病研究,2012,10（7）:481-489.
[12] 中华医学会心血管病学分会循证医学评论专家组,中国老年学学会心脑血管病专业委员会.甘油三酯增高的血脂异常防治中国专家共识. 中华心血管病杂志,2011,39（9）:793-796.
[13] Dongiovanni P,Petta S,Mannisto V,et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol, 2015,63（3）:705-712.
[14] Athyros VG,Tziomalos K,Gossios TD,et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation （GREACE） Study:a post-hoc analysis.Lancet, 2010,376（9756）:1916-1922.
[15] 他汀类药物安全性评价工作组.他汀类药物安全性评价专家共识. 中华心血管病杂志,2014,42（11）:890-894.

Appropriate application of lipid-regulating agents in patients with non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[5]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[6]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[7]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[8]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[9]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[10]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[11]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[12]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[13]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[14]	Song Haiyan, Chen Xi, Zhang Junfei, et al. Application of vorionazole in the treatment of patients with liver failure complicated by pulmonary fungal infection [J]. Journal of Practical Hepatology, 2019, 22(5): 676-679.
[15]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.